Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies

References

• Aladzsity I, Kovacs M, Semsei A, et al. (2009). Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 33:1570–3
   PubMed Web of Science ®Google Scholar
• Anderson KC, Lust JA. (1999). Role of cytokines in multiple myeloma. Semin Hematol 36:14–20
   PubMed Web of Science ®Google Scholar
• Andrie E, Michos A, Kalampoki V, et al. (2009). Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol 83:334–42
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Zheng T, Foss F, et al. (2012). Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv 6:102–14
   PubMedGoogle Scholar
• Banu C, Moise A, Arion CV, et al. (2011). Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life 4:264–8
   PubMedGoogle Scholar
• Birmann BM, Tamimi RM, Giovannucci E, et al. (2009). Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 18:282–8
   PubMed Web of Science ®Google Scholar
• Blay JY, Farcet JP, Lavaud A, et al. (1994). Serum concentrations of cytokines in patients with Hodgkin’s disease. Eur J Cancer 30A:321–4
   PubMed Web of Science ®Google Scholar
• Brockow K, Akin C, Huber M, et al. (2005). IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–23
   PubMed Web of Science ®Google Scholar
• Brown EE, Lan Q, Zheng T, et al. (2007). Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 120:2715–22
   Google Scholar
• Cordano P, Lake A, Shield L, et al. (2005). Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin’s lymphoma. Br J Haematol 128:493–5
   PubMed Web of Science ®Google Scholar
• Cozen W, Gebregziabher M, Conti DV, et al. (2006). Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15:2285–91
   PubMed Web of Science ®Google Scholar
• Cozen W, Gill PS, Ingles SA, et al. (2004). IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103:3216–21
   PubMed Web of Science ®Google Scholar
• Dring AM, Davies FE, Rollinson SJ, et al. (2001). Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. Br J Haematol 112:249–51
   Google Scholar
• Duch CR, Figueiredo MS, Ribas C, et al. (2007). Analysis of polymorphism at site-174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40:265–7
   PubMed Web of Science ®Google Scholar
• Enjuanes A, Benavente Y, Bosch F, et al. (2008). Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 68:10178–86
   PubMed Web of Science ®Google Scholar
• Ennas MG, Moore PS, Zucca M, et al. (2008). Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26:98–103
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–76
   PubMed Web of Science ®Google Scholar
• Galicia JC, Tai H, Komatsu Y, et al. (2004). Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun 5:513–16
   Google Scholar
• Gause A, Keymis S, Scholz R, et al. (1992). Increased levels of circulating cytokines in patients with untreated Hodgkin’s disease. Lymphokine Cytokine Res 11:109–13
   PubMedGoogle Scholar
• Harbord RM, Egger M, Sterne JA. (2006). A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–57
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. (2003). Measuring inconsistency in meta-analyses. BMJ 327:557–60
   PubMed Web of Science ®Google Scholar
• Hoffmann SC, Stanley EM, Darrin Cox E, et al. (2001). Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 72:1444–50
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Di Febo A, et al. (2007). Polymorphism in cytokine genes as prognostic markers in Hodgkin’s lymphoma. Ann Oncol 18:1376–81
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Vilpo J, Vilpo L, et al. (2000). Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica 85:600–6
   PubMed Web of Science ®Google Scholar
• Iakupova EV, Grinchuk OV, Kalimullina D, et al. (2003). Molecular genetic analysis of the interleukin 6 and tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk) 37:420–4
   Google Scholar
• Klein B, Zhang XG, Lu ZY, et al. (1995). Interleukin-6 in human multiple myeloma. Blood 85:863–72
   PubMed Web of Science ®Google Scholar
• Kuku I, Bayraktar MR, Kaya E, et al. (2005). Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm 2005:171–4
   Google Scholar
• Lan Q, Zheng T, Rothman N, et al. (2006). Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107:4101–8
   PubMed Web of Science ®Google Scholar
• Lauta VM. (2003). A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97:2440–52
   PubMed Web of Science ®Google Scholar
• Lichtenstein A, Tu Y, Fady C, et al. (1995). Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248–55
   PubMed Web of Science ®Google Scholar
• Martino A, Buda G, Maggini V, et al. (2012). Could age modify the effect of genetic variants in IL6 and TNF-alpha genes in multiple myeloma? Leuk Res 36:594–7
   Google Scholar
• Mazur G, Bogunia-Kubik K, Wrobel T, et al. (2005). IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96:241–6
   PubMed Web of Science ®Google Scholar
• Meyers CA, Albitar M, Estey E. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788–93
   PubMed Web of Science ®Google Scholar
• Ramadori G, Christ B. (1999). Cytokines and the hepatic acute-phase response. Semin Liver Dis 19:141–55
   PubMed Web of Science ®Google Scholar
• Rausz E, Szilagyi A, Nedoszytko B, et al. (2013). Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis. Br J Haematol 160:216–19
   Google Scholar
• Reich D, Patterson N, Ramesh V, et al. (2007). Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 80:716–26
   PubMed Web of Science ®Google Scholar
• Reittie JE, Yong KL, Panayiotidis P, et al. (1996). Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 22:83–90 , follow 186, color plate VI
   PubMed Web of Science ®Google Scholar
• Rivera-Chavez FA, Peters-Hybki DL, Barber RC, et al. (2003). Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 20:218–23
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Theillet C, Portier M, et al. (1994). Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease. FEBS Lett 341:156–61
   Google Scholar
• Rodriguez S, Gaunt TR, Day IN. (2009). Hardy--Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169:505–14
   PubMed Web of Science ®Google Scholar
• Rose-John S, Scheller J, Elson G, et al. (2006). Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80:227–36
   PubMed Web of Science ®Google Scholar
• Rothman N, Skibola CF, Wang SS, et al. (2006). Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38
   PubMed Web of Science ®Google Scholar
• Schaid DJ, Jacobsen SJ. (1999). Biased tests of association: comparisons of allele frequencies when departing from Hardy--Weinberg proportions. Am J Epidemiol 149:706–11
   PubMed Web of Science ®Google Scholar
• Sfiridaki A, Miyakis S, Tsirakis G, et al. (2005). Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med 43:934–8
   Google Scholar
• Stephens OW, Zhang Q, Qu P, et al. (2012). An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 119:503–12
   PubMed Web of Science ®Google Scholar
• Stone K, Woods E, Szmania SM, et al. (2013). Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One 8:e54610
   Google Scholar
• Suffredini AF, Fantuzzi G, Badolato R, et al. (1999). New insights into the biology of the acute phase response. J Clin Immunol 19:203–14
   PubMed Web of Science ®Google Scholar
• van Rhee F, Stone K, Szmania S, et al. (2010). Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 8:486–98
   PubMedGoogle Scholar
• Vasku JA, Vasku A, Goldbergova M, et al. (2004). Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL). Clin Immunol 113:256–60
   PubMed Web of Science ®Google Scholar
• Vener C, Guffanti A, Pomati M, et al. (2000). Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin’s disease at diagnosis. Leuk Lymphoma 37:333–9
   PubMed Web of Science ®Google Scholar
• Wang SS, Cerhan JR, Hartge P, et al. (2006). Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 66:9771–80
   PubMed Web of Science ®Google Scholar
• Zheng C, Huang DR, Bergenbrant S, et al. (2000). Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109:39–45
   PubMed Web of Science ®Google Scholar
• Zintzaras E. (2010a). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol 9:Article21
   Google Scholar
• Zintzaras E. (2010b). Impact of Hardy--Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur J Epidemiol 25:553–60
   PubMed Web of Science ®Google Scholar
• Zintzaras E. (2012). The power of generalized odds ratio in assessing association in genetic studies with known mode of inheritance. J Appl Stat 39:2569–81
   Web of Science ®Google Scholar
• Zintzaras E, Lau J. (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634–45
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Santos M. (2011). Estimating the mode of inheritance in genetic association studies of qualitative traits based on the degree of dominance index. BMC Med Res Methodol 11:171
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Santos M. (2012). Performance of MAX test and degree of dominance index in predicting the mode of inheritance. Stat Appl Genet Mol Biol 11:Article 4
   Google Scholar